Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

multi-kinase inhibitor AIV001

A prolonged-release multi-kinase inhibitor, with potential anti-angiogenic, anti-fibrotic and antineoplastic activities. Upon intradermal or intratumoral administration, AIV001 targets and binds to several kinases, including vascular endothelial growth factor receptor (VEGFR), and inhibits multiple pathways involved in neovascularization, fibrosis, abnormal cell proliferation and inflammation. This may reduce dermal neovascularization and fibroplasia during wound healing and scarring, reduce inflammation and fibrosis associated with certain skin conditions, and may reduce neovascularization and cell proliferation associated with certain types of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:AIV 001
AIV-001
AIV001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search